Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Patients Treated With Bevacizumab Maintenance: A Target Trial Emulation

NCT06515678 is registered in ClinicalTrials.gov with Groupe Hospitalier Pitie-Salpetriere as lead sponsor.

NCT NCT06515678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06515678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Patients Treated With Bevacizumab Maintenance: A Target Trial Emulation
Lead sponsor
Groupe Hospitalier Pitie-Salpetriere
Phase
Observational
Overall status
Unknown status
Start date
May 20, 2024
Completion date
August 31, 2024
Enrollment
9,464 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adjuvant bevacizumab, antiangiogenic-associated hypertension, hypertension, ovarian cancer